Member Info for AquaeSulis01

Thanks for posting shychap, useful to know the reason and limitations on the sale. Link to the Study itself which actually ought to act as a catalyst to sales of products containing an ingredient that naturally results in melatonin production rather than a potential roadblock.

https://newsroom.heart.org/news/long-term-use-of-melatonin-supplements-to-support-sleep-may-have-negative-health-effects

Must admit, I wonder how Cath's funded work with Croda/Boots sponsorship can be ring-fenced from the Inflammation R&D sponsored by SBTX?

"The inflammation study is looking at how the microbiome can influence and balance the body's response to inflammation specifically related to harmful UVR (sunlight) light. The programme will run until June 2025. "

One of just 2 Acne and Spot Treatments on the filter, the other being a lotion offered in two sizes

https://www.superdrug.com/health/medicated-skin/acne-spots-treatment/c/pt-medicated-acne-treatments?gad_source=7&gclid=CN7zhvrr748DFZ3N8gcdWz4Gpw&query=:ranking:category:Acne%20%26%20Spots%20Treatment

And a promotional offer from Superdrug to complement the Press Release

https://www.superdrug.com/health/medicated-skin/acne-spots-treatment/axisbiotix-ac-acne-support-sachets/p/856126?gclsrc=aw.ds&gad_source=1&gad_campaignid=18158841731&gbraid=0AAAAADp4mz_qjyt2x7dHvrxYQQmkXdlPs&gclid=EAIaIQobChMI-Yut7sTdkAMVJIBQBh0MXQN0EAQYASABEgJn4vD_BwE

Trouble with interpretive text Waldorf. Let me spell it out for you, TW will not be voting to oust Ashman and has no issue with the quality of the Acquisitions and their performance only the price paid

And did TW agree with your views that Askan should be outed or that tge Acquusitions were not accretive?

Toyin, I believe and agree with TW that the Company is now operating profitably on a month-by-month basis, and the acquisitions although not achieving the combined uplift in revenue and profitability anticipated FY25, are also net contributors and not a drain on resources.

Consequently, I have no idea why SA raised as much as he did and you may well be right that he was blindsided by the amount received from Croda end June even though the Superdrug raise took place mid-June. The royalties are paid a quarter in arrears so the cash that arrived end June would be for the March quarter and the variance in expected revenue for Yr end Jun 25 of £4.5-£4.8M may well reflect the potential range of royalty accruals for the Jun quarter from Croda.

Like you I am dissatisfied with the way the Superdrug launch has commenced especially as there is a large war chest available to support a decent marketing campaign, hence why I believe there really must be a lot more to come and I note that the Dermatonic's Manuka Honey is currently subject to a 25% discount promotion in Superdrug so maybe we can expect something similar for Axisbiotix once they have been displayed for circa a month

https://www.asa.org.uk/advice-online/promotional-savings-claims.html

Bazza, the greater than expected cash balance would suggest £4M was not needed for working capital so with respect you are talking purveyor 4rse

Toyin, the main focus for Superdrug will be shifting Christmas stocks i.e. Advent Calendars, rather than all year rounders. For whatever reason Axis has missed the stock changeover for a number of the initial stores and so it is pointless majoring on a co-ordinated advertising campaign until all Stores are ready so my guess is the New Year when some stores will have displayed the axis products long enough to justify a "25% off" normal price campaign. As previously stated, ex Dermatonic's staff know what they are doing even if you believe Santa Ashman does not

I would expect shelf wobblers, promotions and targeted advertising to all take place once the stock is on tge shelves of all the initial 181 stores and not just a handful. This is not the ex Dermatonics staff first roadshow, there are currently heel balm products on promotion and I suspect there will be a major push in the New Year

O'Hara continues to sell to keep the lights on, end of.

Sheephatch, must admit struggling to reconcile your comment with the accompanied Strong Buy Recommendation, there's a job waiting for you drafting SBTX RNS's.

Without knowing what the performance criteria was for 2025 impossible to say whether the earn-out was withheld (accounting for £500K extra cash) or not but will become clear when the audited accounts appear Nov/Dec. What we do know is that adj EBITDA was met despite the revenue miss and that any growth resulting from Umesh Modi is likely to have failed to materialise; ROW sales for Yr ending Jun 2024 were £80,280 yet following the Umesh Modi launch just £33,217 sales were recorded for the first 6 months of FY 2025, contrast this with Yr end Jun 2024 sales of £35,363 for the US which rose to £91,759 in just 6 mths to Dec 24

I assume that most Business's invoice on a monthly basis and certainly for forecasting shychap

First £500k earn out was paid May 2024 according to Dec 24 Accounts

Doubt it, more likely to be this croda patented ingredient

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ppubs.uspto.gov/api/pdf/downloadPdf/12453690?requestToken=eyJzdWIiOiI5ZGQzNDU3Yy03ZjlhLTRjNDktODI2Mi0xY2E0OWQxN2FlYzMiLCJ2ZXIiOiI4MTRhZWQzMS0yMDA4LTQwODMtOWUyMi1jZTBmNmNiZTlmYTQiLCJleHAiOjB9

Regarding the discrepancy between the Management Forecast revenue (£5.3M) and the Singer Note Forecast (£5.1M) just spotted the following difference between the Dec 24 Final results RNS where the £5.3M Forecast came from and the Aug 25 Trading update where the Singer note forecast was quoted.

Dec 24

"The profile of the Group has changed completely this year, and next year's FY25 results will better reflect this with bolstered sales from the in-house strategic pillars with revenues from AxisBiotix-PS sales and the introduction of Croda royalties, and also 12 months of Dermatonics' and nine months of Bio-Tech Solutions' contributions." Nine months of BTS sales = £2M Forecast / 9 = £222K per month

Aug 25

"Management expects to report unaudited revenues of between c.£4.5m-£4.8m1 (FY24: £1.2m), driven by a full year's trading by Dermatonics, eight months trading by Bio-Tech Solutions (BTS), as well as ongoing growth of organic sales of AxisBiotix. Revenues were slightly lower than market expectations due to timing of orders for Dermatonics and BTS, much of which occurred just after the year end."

So the BTS acquisition ran from 12th Oct 24 which explains Singer using 8 mths * £222K rather than SBTX optimistically using 9 mths * £222K would appear to explain the difference.

Yes fair enough Rank, it's just that apart from the "filmed" purchase, I would be surprised if any sales have taken place amongst the 35 psoriasis treatments and 176 Acne products as there appears to have been no promotion to raise awareness amongst Superdrug Customers whatsoever

Toyin, "Shy, the fact is, the acquisitions should have done £5.3m they did £4.5m-£4.8m" did they or does it include Croda revenue in which case the miss was bigger? Anyway, the Acquisitions were bought as an insurance policy in case Croda failed to come to fruition and have long term potential to use BTS to incorporate the lysate(s) into Dermatonic products when we're awash with cash 🤞

Rank, "It’s been on the shelves in a limited number of outlets for a matter of days. The product takes several weeks to take effect…….. Does this answer the question maybe?" Yes and no. Why is it still only on the shelves of a limited number of outlets with zero promotion to raise awareness of these newly stocked products 6 weeks later than expected? When can we expect to see the results of the over £4M fundraise including promotional money to become visible on the net and in Superdrug shops? Staff at Weston-Super-Mare, named as one of the first tranche of Store, still hadn't heard of Axisbiotix as at last weekend.